NCT05496569 - TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma | Biotech Hunter

Enrollment

118

Participants

Timeline

Start Date

December 31, 2022

Primary Completion Date

April 30, 2024

Study Completion Date

December 31, 2024

Conditions

Dedifferentiated Liposarcoma

Interventions

DRUG

TQB3616 capsule

TQB3616 capsule is a cyclin-dependent kinase 4/6 kinase inhibitor

DRUG

TQB3616 placebo

Placebo

Trial Locations (3)

Peking University First Hospital, Beijing

Peking University People's Hospital, Beijing

Zhongshan Hospital Fudan University, Shanghai